• Jinhai Huo, Xianglin L Du, David R Lairson, Wenyaw Chan, Jing Jiang, Thomas A Buchholz, and B Ashleigh Guadagnolo.
• Departments of *Radiation Oncology ∥Biostatistics, University of Texas MD Anderson Cancer Center Divisions of †Management, Policy and Community Health ‡Epidemiology, Human Genetics, and Environmental Sciences §Biostatistics, University of Texas School of Public Health, Houston, TX.
• Am. J. Clin. Oncol. 2015 Jun 1;38(3):235-41.

ObjectivesTo examine the patterns of utilization of radiation therapy, chemotherapy, surgery, and hospice at the end-of-life care for patients diagnosed with metastatic melanoma.MethodsWe identified 816 Medicare beneficiaries toward who were 65 years of age or older, with pathologically confirmed metastatic malignant melanoma between January 1, 2000, and December 31, 2007. We evaluated trends and associations between sociodemographic and health service characteristics and the use of hospice care, chemotherapy, surgery, and radiation therapy.ResultsWe found increasing use of surgery for patients with metastatic melanoma from 13% in 2000 to 30% in 2007 (P=0.03 for trend), and no significant fluctuation in the use of chemotherapy (P=0.43) or radiation therapy (P=0.46). Older patients were less likely to receive radiation therapy or chemotherapy. The use of hospice care increased from 61% in 2000 to 79% in 2007 (P=0.07 for trend). Enrollment in short-term (1 to 3 d) hospice care use increased, whereas long-term hospice care (≥4 d) remained stable. Patients living in the SEER (Surveillance, Epidemiology and End Results) northeast and south regions were less likely to undergo surgery. Patients enrolled in long-term hospice care used significantly less chemotherapy, surgery, and radiation therapy.ConclusionsSurgery and hospice care use increased over the years of this study, whereas the use of chemotherapy and radiation therapy remained consistent for patients diagnosed with metastatic melanoma.

34 keywords...

hide…